Skip to main content
Publications
Rebordosa C , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia-Esteban R , Plana E , Tormos A , Farsani SF, Perez-Gutthann S , Pladevall-Vila M . Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts . Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429
Oberprieler NG, Kovesdy CP, Layton JB , Gay A, Farjat AE, Liu F, Johannes CB , Pladevall-Vila M , Vizcaya D. Early use and effectiveness of finerenone in US patients with CKD and type 2 diabetes: a FOUNTAIN platform analysis . Poster presented at the Kidney Week 2023; November 2, 2023. Philadelphia, PA.
Tormos A , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia Esteban R , Plana E , Farsani SF, Perez-Gutthann S , Pladevall-Vila M , Rebordosa C . Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D) . Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):585. doi: 10.1002/pds.5687
Thomsen RW, Andersen IT, Kristensen FP, Munch PV, Pladevall-Vila M , Johannes C , Saigi-Morgui N , Ziemiecki R , Layton J , Vizcaya D, Gay A, Farjat A, Liu F, Oberprieler N, Christiansen CF. Clinical profile and kidney function of SGLT2i and GLP-1RA new users with CKD and type 2 diabetes in Denmark: a nationwide population-based study part of the FOUNTAIN platform . Presented at the 59th Annual Meeting European Association for the Study of Diabetes (EASD) 2023; October 4, 2023. Hamburg, Germany.
Johannes CB , Beachler DC, Layton JB , Danysh HE , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M , Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3
Danysh HE , Johannes CB , Beachler DC, Layton JB , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M , Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4
Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA, Pladevall-Vila M , Garcia de Albeniz X , Hunt PR, Gilsenan A , Beachler DC, Ke Zhou C. Description of acute kidney injury and breast cancer outcome validation processes across three databases . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Danysh HE , Layton B , Beachler DC, Arana A , Pladevall-Vila M , Schmid R, Calingaert B , Ziemiecki R , Hunt PR, Gilsenan A , Johannes C . Validation of acute outcomes among patients with type 2 diabetes mellitus in Medicare: a pilot study . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.
Zhou CK, Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA, Pladevall-Vila M , Garcia-Albeniz X , Gangemi K, Yin R, Ruzafa JC, Gilsenan A , Beachler DC. Validity of claims-based algorithms to identify acute kidney injury, acute liver injury, severe complications of urinary tract infections, breast cancer, and bladder cancer among patients with type 2 diabetes: a pilot study . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):317. doi: 10.1002/pds.4864
Gil M, Romio S, Scotti L, Leal I, Masclee GMC, Schmedt N, Varas-Lorenzo C, Pladevall-Vila M , Smits MM, Bezemer I, Seeger JD, de Beradis G, Pecchioli S, Trifiro G, McGrogan A, Rijnbeek P, Sturkenboom M. Risk of hemorrhagic stroke associated with non-insulin blood glucose lowering drugs. Results from the SAFEGUARD project . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):428-9.
Masclee GMC, Leal I, Scotti L, De Berardis G, Bezemer I, Gil M, McGrogan A, Schmedt N, Seeger JD, Trifiro G, Pecchioli S, Pladevall-Vila M , Smits MM, Rijnbeek P, Sturkenboom M, Romio SA. Use of non-insulin blood glucose lowering drugs and the risk of acute pancreatitis . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):246-7.